Additional file 4 of A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology

Additional file 4: Supplementary Table 4. Tabular survey of validation results to determine DNA panel sequencing performance. SNPs and InDels were validated with direct Sanger sequencing, 1p/19q codeletions with microsatellite PCR analysis, and homozygous deletion of CDKN2A as well as highcopy amplification of EGFR with target specific quantitative PCR. Medulloblastoma subgroups were validated by comparison to immunohistochemically determined subgroups with antibodies against ß-Catenin, Yap1, p75-NGFR and OTX2 [10]. InDel: small insertion/deletion, nd: not determined, RET: retention, SNP: single nucleotide variant, WT: wildtype.